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Abstract
Mutations that alter signaling of RAS/MAPK-family proteins give rise to a group of Mendelian
diseases known as RASopathies. However, among RASopathies, the matrix of genotype-
phenotype relationships is still incomplete, in part because there are many RAS-related pro-
teins and in part because the phenotypic consequences may be variable and/or pleiotropic.
Here, we describe a cohort of ten cases, drawn from six clinical sites and over 16,000
sequenced probands, with de novo protein-altering variation in RALA, a RAS-like small
GTPase. All probands present with speech and motor delays, and most have intellectual
disability, low weight, short stature, and facial dysmorphism. The observed rate of de novo







Citation: Hiatt SM, Neu MB, Ramaker RC,
Hardigan AA, Prokop JW, Hancarova M, et al.
(2018) De novo mutations in the GTP/GDP-binding
region of RALA, a RAS-like small GTPase, cause
intellectual disability and developmental delay.
PLoS Genet 14(11): e1007671. https://doi.org/
10.1371/journal.pgen.1007671
Editor: Gregory P. Copenhaver, The University of
North Carolina at Chapel Hill, UNITED STATES
Received: June 27, 2018
Accepted: August 30, 2018
Published: November 30, 2018
Copyright: © 2018 Hiatt et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which
permits unrestricted use, distribution, and
reproduction in any medium, provided the original
author and source are credited.
Data Availability Statement: All relevant variant
data are supplied within the paper or in supporting
files. Complete genome data for Proband 1 is
available via dbGAP (https://www.ncbi.nlm.nih.gov/
projects/gap/cgi-bin/study.cgi?study_id=
phs001089.v3.p1). Project Accession Number:
phs001089, Individual A-00281-C. Complete
genome data for Proband 11 will be available in
dbGAP. Complete genome and exome data for
other probands is not available due to privacy and
IRB reasons.
RALA variants in affected probands is significantly higher (p = 4.93 x 10−11) than expected
from the estimated random mutation rate. Further, all de novo variants described here affect
residues within the GTP/GDP-binding region of RALA; in fact, six alleles arose at only two
codons, Val25 and Lys128. The affected residues are highly conserved across both RAL-
and RAS-family genes, are devoid of variation in large human population datasets, and sev-
eral are homologous to positions at which disease-associated variants have been observed
in other GTPase genes. We directly assayed GTP hydrolysis and RALA effector-protein
binding of the observed variants, and found that all but one tested variant significantly
reduced both activities compared to wild-type. The one exception, S157A, reduced GTP
hydrolysis but significantly increased RALA-effector binding, an observation similar to that
seen for oncogenic RAS variants. These results show the power of data sharing for the inter-
pretation and analysis of rare variation, expand the spectrum of molecular causes of devel-
opmental disability to include RALA, and provide additional insight into the pathogenesis of
human disease caused by mutations in small GTPases.
Author summary
While many causes of developmental disabilities have been identified, a large number of
affected children cannot be diagnosed despite extensive medical testing. Previously
unknown genetic factors are likely to be the culprits in many of these cases. Using DNA
sequencing, and by sharing information among many doctors and researchers, we have
identified a set of individuals with developmental problems who all have changes to the
same gene, RALA. The affected individuals all have similar symptoms, including intellec-
tual disability, speech delay (or no speech), and problems with motor skills like walking.
In nearly all of these cases (10 of 11), the genetic change found in the child was not inher-
ited from either parent. The locations and biological properties of these changes suggest
that they are likely to disrupt the normal functions of RALA. Functional experiments also
show that the genetic changes found in these individuals alter two key functions of RALA.
Together, we have provided evidence that genetic changes in RALA can cause develop-
mental disabilities. These results will allow doctors and researchers to identify additional
children with the same condition, providing a clinical diagnosis to these families and lead-
ing to new research opportunities.
Introduction
Developmental delay and intellectual disability (DD/ID) affect about 1–2% of individuals
worldwide [1]. Many highly penetrant genetic variants underlying DD/ID have been identi-
fied, but a large fraction of disease risk remains unexplained [2, 3]. While some DD/ID-cases
may result from environmental factors and small-effect common variants [4], it is likely that
many probands harbor pathogenic, highly penetrant variation in as-yet-unknown disease-
associated genes.
The RASopathies are a group of genetic conditions often associated with developmental
disorders [5], having in common mutational disruption of genes in the RAS/MAPK pathway
that alter patterns of signal transduction. RASopathies are individually rare and pleiotropic but
are collectively one of the most common causes of developmental disorders. Associated
RALA mutations and neurodevelopmental disorders
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features include neurocognitive impairment, craniofacial dysmorphology, anomalies of the
cardiovascular and musculoskeletal systems, cutaneous lesions, and increased risk of tumor
formation [6]. For example, variation in HRAS is associated with Costello Syndrome
(MIM:218040), variation in KRAS is associated with Noonan Syndrome 3 (MIM:609942) and
Cardiofaciocutaneous syndrome 2 (MIM:615278), and variation in NRAS has been observed
in probands with Noonan syndrome 6 (MIM:613224) and other RASopathy-associated pheno-
types [7].
Given the genetic and phenotypic heterogeneity among DD/ID in general and RASopathies
in particular, collaboration and data sharing among clinicians, researchers, and sequencing
centers is necessary to enable, or accelerate, discoveries of new forms of disease. One tool to
facilitate such collaborations is GeneMatcher, launched in 2013 as a way to connect researchers
and clinicians with interests in specific genes [8].
Here, we present details of a cohort, assembled via GeneMatcher, of eleven total probands
(including one set of monozygotic twins) with protein-altering variation in RALA, which
encodes a RAS-like small GTPase; the variants arose de novo in ten of these probands. All pro-
bands present with developmental delay. Detailed phenotyping, computational analyses of
observed variation, and functional studies lead to the conclusion that missense variation affect-
ing the GTPase activity and downstream signaling of RALA underlies a new neurodevelop-
mental RASopathy-like disorder.
Results
This study originated as a collaboration facilitated by GeneMatcher through shared interest in
RALA as a result of observations from exome sequencing (ES) or genome sequencing (GS) as
part of DD/ID-related clinical or research testing. In the Methods and Supporting Information
(S1 Text, S1 Table), we describe the research sites that identified one or more affected pro-
bands reported in this study, the methods used for sequencing and analysis, and related details.
In total, we identified RALA mutations in eleven affected probands from ten unrelated fami-
lies. These variants were identified from a combined set of over 16,000 probands sequenced by
six groups who independently submitted RALA to GeneMatcher (Table 1, S1 Table).
Phenotypic details
All eleven probands presented with speech problems, including absent speech in seven and
speech delay in the remaining four. Ten of the eleven probands are reported to have hypotonia,
with eight unable to walk. Intellectual disability was specifically noted for 8 of 11, (but not
ruled out for the remaining three, see Table 1). Birth measurements were available for nine
probands and three (33%) reported either length or weight (or both) at less than the tenth per-
centile. Height and weight measurements at last examination were available for all probands
(except for height in one). Six of ten probands (60%) were reported to have heights less than
the 10th percentile at last examination, while eight of eleven (73%) were reported to have
weights less than the 10th percentile. Three probands had head circumference measurements
greater than or equal to the 90th percentile at last evaluation. Nine of eleven probands were
reported to have dysmorphic facial features. Several consistent features were observed, includ-
ing a broad, prominent forehead, horizontal eyebrows, epicanthus, mild ptosis, slightly ante-
verted nares, wide nasal bridge, short philtrum, thin upper lip vermillion with an exaggerated
Cupid’s bow, pointed chin, and low-set ears with increased posterior angulation (Fig 1).
Additional common but variable features were observed: seizures were present in most pro-
bands (6/11), as were structural brain abnormalities detected by MRI (9/11). Six of eleven pro-
bands were reported to have skeletal anomalies such as clinodactyly (3 of 6) and/or 2/3 toe
RALA mutations and neurodevelopmental disorders
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syndactyly (2 of 6). None of the probands are reported to have had cancer. Clinical summaries
with additional details are available in Supporting Information (S2 Text).
Molecular characterization of variation
Genetic variation within this cohort includes eight de novo heterozygous missense variants in
nine probands (including the monozygotic twin pair), one de novo heterozygous in-frame
deletion of one amino acid, and one heterozygous premature stop of unknown inheritance
(Table 1, Fig 2A). Except for R176X (see below), all observed variants are absent from gno-
mAD [10] and TopMed genomes (“Bravo”) [11]. These variants have scaled CADD scores
ranging from 22.1 to 41 suggesting they are highly deleterious, similar to the majority of muta-
tions previously reported to cause Mendelian diseases [9].
Seven probands (1–7), including the monozygotic twin pair, harbor recurrent de novo vari-
ants affecting one of only two codons, those encoding residues Val25 and Lys128, while the
remaining three de novo variants affect Asp130, Ser157, and Ala158. All of these residues are
computationally annotated as one of 24 residues, within a total protein length of 206 amino
acids, that form the GTP/GDP-binding region of the RALA protein (Fig 2, Methods). While
Val25 does not directly interact with GTP/GDP, variation observed at this position (Val25Met
and Val25Leu) would likely result in distortion of the structure of the GTP/GDP-binding
pocket (Fig 2B and 2C; S1 Fig). Lys128, Asp130, and Ser157 all form hydrogen bonds with
GTP/GDP in the wild type protein (Fig 2B and 2C; S2 Fig, S3 Fig, S4 Fig). Although Lys128Arg
would retain the positive charge of the side chain, steric hindrance resulting from the larger
size of the Arg side chain would likely result in disruption of this binding pocket (S2 Fig). Both
Asp130Gly and Ser157Ala are predicted to result in loss of hydrogen bond formation (Fig 2B
and 2C; S3 Fig, S4 Fig). The remaining de novo variant, an in-frame deletion of Ala158, results
Fig 1. Facial features of individuals with variation in RALA. Overlapping features include a broad, prominent forehead, horizontal eyebrows, epicanthus, mild ptosis,
slightly anteverted nares, wide nasal bridge, short philtrum, thin upper lip vermillion with an exaggerated Cupid’s bow, pointed chin, and low-set ears with increased
posterior angulation.
https://doi.org/10.1371/journal.pgen.1007671.g001
RALA mutations and neurodevelopmental disorders
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in a shift of Lys159 into the GTP/GDP binding region of RALA, which likely hinders GTP/
GDP binding (S5 Fig). Variation at all five of these residues is thus structurally predicted to
alter GTP/GDP binding. This conclusion is consistent with the high degree of conservation at
these residues throughout evolution of RALA (S6 Fig) as well as in other related genes includ-
ing HRAS, KRAS, and NRAS (S7 Fig) and RAP1A/B and RHOA[12].
The predicted nonsense variant Arg176X in proband 11 lies within the last exon of RALA,
and thus may not result in nonsense-mediated decay (NMD) of the transcript. This would
yield a protein that lacks the 29 C-terminal residues (S8 Fig), which are known to contain at
least two critical regulatory regions. Phosphorylation of Ser194 by Aurora kinase A (AURKA)
activates RALA, affects its localization, and results in activation of downstream effectors like
RALBP1 [13, 14]. Additionally, the C-terminal CAAX motif (CCIL in the case of RALA) is
essential for proper localization and activation of RALA via prenylation of Cys203 [15, 16].
Fig 2. Variation observed in RALA clusters in GTP/GDP-binding regions. A. Linear model of RALA, including GTP/GDP-binding regions (depicted in yellow, as
defined by molecular modeling data) and the CAAX motif (CCIL in the case of RALA; depicted in green). Positions of amino acid residues that form the GTP/GDP-
binding region are listed below the model, and residues within those regions are listed above the model. Residues affected by variation observed here are shown in red.
The predicted protein changes for described variation are shown above the affected amino acid residues. B. Positions of RALA amino acid residues affected by variation
relative to the GDP molecule. C. A zoomed in view of the variation observed within the GTP/GDP-binding region. GDP is shown in a licorice representation in orange.
The RALA protein is shown in a cartoon representation in green, with the mutated residues in licorice representation. V25 is in yellow, K128 in blue, D130 in red, S157
in magenta, and A158 in black. Hydrogen bonds between the side chains of these amino acids and GDP are shown as black dashed lines. See S1–S5 and S8 Figs for
consequences of individual variants on the protein structure.
https://doi.org/10.1371/journal.pgen.1007671.g002
RALA mutations and neurodevelopmental disorders
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Enrichment and clustering of missense variation
We next assessed whether the de novo variants in our cohort were enriched compared to that
which would be expected in the absence of a disease association. The background frequency of
de novo missense or loss-of-function variation in RALA (6.16 x 10−6 per chromosome) was
taken from Samocha et al. [17], in which the authors estimated the expected rates of de novo
mutation based on gene length and trinucleotide sequence context. In our study, eight unre-
lated individuals were drawn from cohorts of at least 400 proband-parent trios, collectively
spanning 16,086 probands (S1 Table). When comparing the frequency of observed de novo
variation to the expected background frequency of de novo missense or loss-of-function varia-
tion in RALA (6.16 x 10−6 per chromosome) [17], we find a highly significant enrichment for
de novo variants in affected probands (8 observed de novo variants in 32172 screened alleles vs.
0.198 expected, Exact Binomial test p = 4.93 x 10−11). We note that this p-value is likely conser-
vative, as it results from comparison of the observed rate to the expected frequency of de novo
variation over the entire gene. However, six of the nine de novo alleles affect only two codons,
and all observed de novo variants are within the GTP-interacting space of 24 residues (11.7%
of the 206-aa protein, Fig 2A). This clustering likely reflects a mechanism of disease that
depends specifically on alterations to GTP/GDP binding and, subsequently, RALA signaling.
Population genetic data also support pathogenicity of the observed de novo variants. RALA
has a pLI score of 0.95 in ExAC [10], suggesting that it is intolerant to loss-of-function varia-
tion. While RALA has an RVIS score rank [18] of 50.45%, it also has an observed/expected
ratio percentile of 0.92%, a score that has been suggested to be more accurate for small proteins
wherein observed and expected allele counts are relatively small [19]. Furthermore, population
genetic data also support the likely special relevance of mutations in the GTP/GDP-binding
pocket. No high-quality (“PASS” only) missense variants are observed at any frequency at any
of the 24 GTP/GDP-coordinating residues in either gnomAD [10] or BRAVO [11]; in contrast,
there are missense variants observed at 34 of the 182 RALA residues outside the GTP/GDP-
interaction region (S2 Table). This distribution across RALA is likely non-random (Fisher’s
exact test p = 0.017) and suggestive of especially high variation intolerance in this region of
RALA.
Comparison to disease-associated variation in other small GTPases
RALA and RAS-family genes have a high degree of similarity, and germline variation in several
RAS-family GTPases is known to be associated with developmental disorders [5]. Compari-
sons of phenotypes observed here to those reported in these RASopathies suggest considerable
overlap, including DD/ID, growth retardation, macrocephaly, high broad forehead, and mildly
dysplastic dorsally rotated ears. Further, we compared the specific variants observed here to
variants in HRAS, KRAS, or NRAS previously reported as pathogenic for RASopathies (S3
Table, S7 Fig). De novo heterozygous missense variation at Val14 of KRAS, the homologous
equivalent of Val25 in RALA, was previously reported in four unrelated individuals with Noo-
nan syndrome [20, 21]. Functional studies showed that this variant may alter intrinsic and
stimulated GTPase activity and may increase the rate of GDP release [20, 21]. A de novo vari-
ant in HRAS at Lys117, the homologous equivalent of Lys128 in RALA, was found in two
unrelated probands with Costello Syndrome [22]. Lastly, a de novo HRAS variant at Ala146,
the homologous equivalent of Ala158 in RALA, was reported in at least three patients with
Costello Syndrome [23]. Variation at this residue has also been reported as a recurrent somatic
variant in colorectal cancers [24].
Additionally, a recent study identified three probands with brain malformations and de
novo missense variants in ARF1, encoding a small GTP-binding protein [25]. The location of
RALA mutations and neurodevelopmental disorders
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one of the observed missense variants, ARF1 K127E, is analogous to RALA K128, a residue
affected by variation in our cohort. This previous study also found that ARF1 missense varia-
tion is depleted from the general human population, particularly for missense variation affect-
ing the GTP/GDP-binding region; that conclusion is consistent with the observation here that
missense variants are not observed in the GTP/GDP-binding residues of RALA in large popu-
lation databases.
Functional analysis
We investigated the functional consequences of the variants described above by expressing
and purifying recombinant RALA proteins, and then measuring their abilities to hydrolyze
GTP (see Methods). While wild-type RALA showed robust GTPase activity under these exper-
imental conditions, all mutants tested here exhibited a dramatic reduction in GTPase activity,
including a mutant RALA that was not observed in probands but which carries a missense sub-
stitution, G23D, homologous to the G12D KRAS or HRAS variant commonly observed in
tumors (Fig 3A). As GTPase activity of mutant RAS family proteins alone is not always a clear
indication of downstream effects [20, 21], we also assessed binding of these mutants to a
RALA effector protein using an ELISA-based method (see Methods). In this assay, recombi-
nant G23D RALA protein exhibited approximately two-fold increased binding (p< 0.0001,
Fig 3B), as anticipated for a constitutively active gain-of-function alteration [20, 26]. V25L,
V25M, D130G and R176X each showed a 2-5-fold reduction in effector binding compared to
wild-type (each p< 0.0001, Fig 3B). In contrast, the S157A mutant exhibited increased binding
compared to wild-type, suggesting that it may act in a constitutively-active manner similar to
G23D (p< 0.0001, Fig 3B). We note that while there is some variation among mutants in the
efficiency of protein production and purification (Methods, S9 Fig), whether or not one nor-
malizes to relative band intensity from Western blots of purified protein does not qualitatively
affect these conclusions (S10 Fig).
Other candidate variants in probands with RALA variants
In this and other cases of rare disease sequencing, it is important to consider other variation in
any given patient that may be pathogenic. In six of the eleven cases presented here, the RALA
variant was found to be the only plausible candidate. In five cases, other variants were discov-
ered that were also initially considered as potential disease-causing mutations (Table 1, S2 Text).
Proband 2 has a hemizygous variant in FLNA (p.V606L), inherited from his unaffected hetero-
zygous mother. Phenotype comparison, consultation with a filaminopathy disease expert, and
application of the ACMG variant interpretation guidelines [27] resulted in the scoring of this
variant as a VUS. FLNA is an interaction partner of RALA [28], but the disease relevance of this
variant is unclear. Proband 7 has a de novo variant in SHANK2 (p.A1101T); however, this allele
is present in gnomAD three times and thus is not likely to be a highly penetrant allele resulting
in DD/ID. Proband 8 has a variant in SCN1A, p.R187Q; however, this variant was inherited
from an unaffected father, is present in gnomAD in one heterozygote, and, according to the
referring clinician, the phenotype observed in the proband is not consistent with Dravet syn-
drome. Finally, proband 10 carries a paternally-inherited 1.349 Mb duplication of 1q21.1-q21.2.
This duplication has been reported to be associated with mild to moderate DD/ID, autism spec-
trum disorders, ADHD and behavioral problems, and other variable features [29]. While the
patient may have some phenotypic features of this duplication, the patient’s MRI findings and
severity of delays are not likely explained by this inherited duplication.
Proband 11 carries a nonsense variant, R176X, which is unusual given the apparent speci-
ficity for the GTP/GDP-binding region of RALA observed in the other cases in our cohort.
RALA mutations and neurodevelopmental disorders
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Fig 3. Missense variation in RALA affects GTPase activity and RALA effector binding. A. GTPase activity of purified
recombinant RALA proteins was assessed using a luminescence assay. Raw luminescence values (measuring remaining free
RALA mutations and neurodevelopmental disorders
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Clinically, we consider the R176X to be a variant of uncertain significance for several reasons.
The R176X allele has been observed twice in the Bravo genome database, and parental DNA
for this proband was not available, so we do not know whether the variant is de novo or inher-
ited. In addition, the proband has microcephaly and more profound delays than others in the
cohort, and also has large regions of homozygosity consistent with parental consanguinity.
These regions of homozygosity suggest an additional and/or more complex molecular
pathogenesis.
Discussion
The application of genome sequencing to clinical settings is rapidly expanding our knowledge
of mutations that cause rare disease, and has engendered new strategies for analysis, new
rubrics for molecular pathology, and new platforms for collaboration. Here we apply these
advances to show that mutations in the GTP/GDP-binding region of RALA cause develop-
mental and speech delay, together with minor dysmorphic features. Mutations in RAS family
members and RAS signaling pathways are well-recognized causes of several dysmorphic syn-
dromes and cancer, but germline mutations in RALA have not to our knowledge been previ-
ously associated with disease. Our results add to basic knowledge about the biology and
function of RAS super-family members, raise new questions about the molecular pathogenesis
of mutations that affect small GTPases, and have important implications for clinical genomics.
Among the RAS super-family of small GTPases, RALA and RALB are among the most
closely related to the RAS subfamily (~50% amino acid similarity), and function as a third arm
of the RAS effector pathway in addition to RAF and PI3K activation [5]. RALA and RALB
have different expression patterns—RALA is broadly expressed whereas expression of RALB is
enriched in endocrine tissues [30]—but also exhibit some degree of genetic redundancy: in
gene-targeted mice, loss of function for RALA causes a severe neural tube defect that is exacer-
bated by simultaneous loss of RALB [31]. In neuronal culture systems, RALA has been impli-
cated in the development, plasticity, polarization, migration, branching, and spine growth of
neurons [32–36], as well as the renewal of synaptic vesicles and trafficking of NMDA, AMPA,
and dopamine receptors to the postsynaptic membrane [28, 35, 37].
Previous studies have evaluated the effects of RALA in multiple ways, including through
loss of function studies (e.g., mouse knockouts, RNA interference, etc.), and designed muta-
tional alterations to GTP/GDP hydrolysis, suggesting that multiple types of RALA perturba-
tion have molecular and cellular consequences. Several aspects of our results suggest that
developmental delay in humans is not caused by a simple loss-of-function of RALA. First, no
clearly pathogenic loss-of-function (i.e., nonsense, frameshift, splice-site) alleles were reported
to GeneMatcher or exist in the literature to our knowledge. Second, in mice, heterozygosity for
loss of function does not obviously affect development or viability [31]. Third, the de novo mis-
sense alleles described here are clearly enriched in GTP/GDP-binding residues, with six alleles
recurring at only two codons. Fourth, missense RALA alleles in the general population all lie
outside of the GTP/GDP-binding residues, suggesting selective depletion similar to that seen
for other small GTP-binding proteins [25]. Finally, multiple disease-associated RALA
GTP) were subtracted from 100 to calculate activity, and were then normalized to a no template control (NTC). WT, wild-type
RALA. G23D, predicted constitutively active mutant (not from a proband). �� indicates p-value = 0.0015 compared to WT, ���
indicates p-value = 0.0003, and ���� indicates p-value< 0.0001 compared to WT. Mean values of one experiment performed in
triplicate are shown. B. Binding of purified recombinant RALA proteins to an effector molecule was assessed using an ELISA-
based assay. Absorbances were normalized to a no template control (NTC). Mean values of one experiment performed in
triplicate are shown. WT, wild-type RALA. ���� indicates p-value< 0.0001 compared to WT. #### indicates p-value< 0.0001
compared to NTC. ### indicates p-value = 0.0001 compared to NTC.
https://doi.org/10.1371/journal.pgen.1007671.g003
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positions observed here are homologous to positions at which mutations in other small
GTPases have been shown to alter GTPase activity and thereby lead to disease. Combined,
these observations suggest that reduced RALA dosage is not per se pathogenic, but instead
that disease results from a mechanism that depends specifically on alterations to GTP/GDP
binding dynamics. In functional assays, we found that all of the proband alleles exhibited
reduced GTPase activity, similar to most oncogenic RAS alleles. However, they exhibited
variability in their ability to bind RALA effector protein, with one showing increased effector
binding, as is typically observed in tumor-associated RAS alleles, and the others all reducing
effector binding. Similar variability of in vitro functional effects were reported for KRAS
GTP/GDP-binding domain mutations observed in patients with developmental disorders
[21]. Thus, while a commonality of altered GTP/GDP-binding is apparent, our results are
consistent with multiple potentially relevant molecular mechanisms, including 1) altered lev-
els of GTPase activity, 2) altered GTP/GDP release; and 3) altered regulatory and/or effector
protein binding.
We note that the phenotypes of individuals with the same allele were not qualitatively more
similar to one another than phenotypes of individuals with distinct alleles (see Table 1). For
example, seizures were observed for five of 10 probands with a de novo missense variant,
including only one of three probands with V25M and one of two probands with K128R. Thus,
genetic, environmental, or stochastic variability beyond the specific molecular effects of any
given RALA mutation also contribute to disease manifestation. Additional functional assess-
ments of RALA variants and larger cohorts of affected individuals are needed to clarify the rel-
evant molecular mechanisms and the extent of genotype-phenotype correlations within the
umbrella of RALA-associated disease.
In summary, we show that de novo missense variation disrupting the GTP/GDP-binding
functions of RALA lead to developmental delay, intellectual disability, and related phenotypes.
These observations add to the diverse and pleiotriopic group of Mendelian disorders caused
by variation in RAS-family GTPases and related RAS pathways.
Materials and methods
Ethics statement
Informed consent for participation in research was obtained from all families described here.
Further, written informed consent to publish clinical photographs was also obtained for all
probands pictured in Fig 1. Additional research approval details are as follows. Proband 1
enrolled in a study approved by review boards at Western (20130675) and the University of
Alabama at Birmingham (X130201001). Proband 2 enrolled in a research study approved by
the Ethics Committee of University Hospital Motol, Prague (20120627). Proband 3 was
sequenced and analyzed in a diagnostic setting, and oral consent was obtained for research
purposes approved by Kaiser Permanente Hawaii. Probands 4 and 5 were sequenced and ana-
lyzed in a diagnostic setting, and written consent was obtained for research purposes approved
by the Agence Re´gionale de Sante´, Iˆle de France. Proband 6 enrolled in a research study
approved by the Institute for Genomic Medicine at Columbia University (AAAO8410). Pro-
bands 7 and 10 enrolled in a study approved by the Western Institutional Review Board
(1175206). Proband 8 enrolled in a study approved by review boards at the University of Ten-
nessee Health Science Center (UTHSC201801). Proband 9 was sequenced and analyzed in a
diagnostic setting, and written consent was obtained for research purposes approved by
Orlando Health. Proband 11 enrolled in a research study approved by a review board at Uni-
versity of Alabama at Birmingham (F170303004).
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Exome/genome sequencing
Exome sequencing (ES) or genome sequencing (GS) was performed at one of six sites, in either
a research or clinical setting. Named sites and additional details, including cohort sizes used in
p-value calculations, are provided in Supporting Information (S1 Text, S1 Table).
Three dimensional modeling
The protein structure determined by Holbourn et al. [38] was used for the assessment of the
potential effect of the mutations on RALA activity (PDB ID: 2BOV). The structure was visual-
ized using PyMOL 0.99rc6 [39]. Additional protein modeling was performed as previously
described [40]. The GTP/GDP-binding residues of RALA were defined as those in which any
atom of a residue (side chain or backbone) lies within 1.5 angstroms of an atom of the ligand.
Cloning, protein expression, and purification
RALA cDNA was synthesized (Integrated DNA Technologies, Skokie, IL, USA) based on the
coding sequence of NM_005402.3, with substitutions identified in patients described here
(probands 1–9, 11; see Note below) used to represent variation. Following PCR amplification,
coding sequences were cloned into Champio pET302/NT-His (ThermoFisher Scientific, Wal-
tham, MA, USA, # K630203) using Gibson Assembly Master Mix (New England BioLabs, Ips-
wich, MA, USA, #E2611). All RALA coding sequences were Sanger sequenced and compared
to NM_005402.3. The only differences within the coding regions of RALA were those observed
in the probands. Single Step (KRX) Competent Cells (#L3002, Promega Corporation, Madison
WI, USA) were transformed with plasmids, and bacteria were grown overnight at 37˚C in LB
plus ampicillin. Bacteria were diluted 1:100 in fresh LB plus 0.05% glucose and 0.1% rhamnose
to induce a 6-His-tagged recombinant RALA protein. Bacteria were collected after 8 h incuba-
tion at 25˚C, and snap-frozen on dry ice. 6-His-tagged proteins were purified using Dynabeads
His-Tag Isolation and Pulldown (#10103D, ThermoFisher Scientific, Waltham, MA, USA)
according to the manufacturer’s protocol. Protein purity was assessed using standard SDS-
PAGE and Coomassie Blue staining. Protein concentration was quantified using a Take3
microplate reader (BioTek, Winooski, VT, USA) by assessing absorbance at 280 nm. Protein
amounts were normalized among samples in Dynabead elution buffer prior to use in assays.
GTPase activity
GTPase activity of 0.95 μg of purified, recombinant proteins was assessed using the GTPase-
Glo Assay (#V7681, Promega Corporation, Madison WI, USA). Luminescence was quantified
using an LMax II 384 Microplate Reader (Molecular Devices, San Jose, CA, USA).
Effector-binding assay
Binding of purified, recombinant proteins to a proprietary Ral effector protein was assessed
using the RalA G-LISA Activation Assay Kit (#BK129, Cytoskeleton, Inc. Denver, CO), as per
the manufacturer’s protocol. Briefly, purified RALA protein was incubated in the presence or
absence of 15 μM GTP (#P115A, Promega) for 1.5 h at 25˚C, then 23.75 ng of purified RALA/
GTP mixture was applied to the Ral-BP binding plate. A Take3 microplate reader was used for
quantification of this colorimetric assay.
Western blot
Purified proteins were detected using a polyclonal RALA Antibody (#3526S, Cell Signaling
Technology, Danvers, MA, USA) at a dilution of 1:1000, and an anti-rabbit IgG secondary
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antibody (#926–32211, IRDye 800CW Goat anti-Rabbit IgG, Li-cor, Lincoln, NB, USA) at a
dilution of 1:20,000. Proteins were also detected using a 6x-His Tag monoclonal antibody
(#MA1-21315, ThermoFisher Scientific, Waltham, MA, USA) at a dilution of 1:1000, and an
anti-mouse IgG secondary antibody (#102673–408, VWR, Radnor, PA, USA) at a dilution of
1:20,000. These antibodies were used to confirm protein levels and determine appropriate
binding of the RALA antibody (See panel B of S9 Fig). An Odyssey CLx Imaging System (Li-
cor, Lincoln, NB, USA) was used to visualize the Western. Relative quantification of the image
was performed using Image J (https://imagej.net/).
We note that while we attempted to study the effects of all variation observed here, Proband
10 was identified after functional validation began, and the recombinant protein with the
K128R variant (observed in probands 6 and 7) was not able to be expressed and purified con-
sistently. Thus GTPase and G-LISA experiments were not performed using K128R or A158del
mutants.
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